The role of the cancer testis antigen PRAME in tumorigenesis and immunotherapy in human cancer
- PMID: 32022332
- PMCID: PMC7106952
- DOI: 10.1111/cpr.12770
The role of the cancer testis antigen PRAME in tumorigenesis and immunotherapy in human cancer
Abstract
Preferentially expressed antigen in melanoma (PRAME), which belongs to the cancer/testis antigen (CTA) gene family, plays a pivotal role in multiple cellular processes and immunotherapy response in human cancers. PRAME is highly expressed in different types of cancers and is involved in cell proliferation, apoptosis, differentiation and metastasis as well as the outcomes of patients with cancer. In this review article, we discuss the potential roles and physiological functions of PRAME in various types of cancers. Moreover, this review highlights immunotherapeutic strategies that target PRAME in human malignancies. Therefore, the modulation of PRAME might be useful for the treatment of patients with cancer.
Keywords: PRAME; immunotherapy; oncogene; proliferation; tumorigenesis.
© 2020 The Authors. Cell Proliferation Published by John Wiley & Sons Ltd.
Conflict of interest statement
The authors declare that they have no conflict of interest.
Figures

Similar articles
-
Cancer/Testis Antigens: Expression, Regulation, Tumor Invasion, and Use in Immunotherapy of Cancers.Immunol Invest. 2016 Oct;45(7):619-40. doi: 10.1080/08820139.2016.1197241. Epub 2016 Sep 7. Immunol Invest. 2016. PMID: 27603913 Review.
-
Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME?Cancers (Basel). 2019 Jul 15;11(7):984. doi: 10.3390/cancers11070984. Cancers (Basel). 2019. PMID: 31311081 Free PMC article. Review.
-
The Utilization of PRAME in the Diagnosis, Prognosis, and Treatment of Melanoma.Cells. 2024 Oct 20;13(20):1740. doi: 10.3390/cells13201740. Cells. 2024. PMID: 39451258 Free PMC article. Review.
-
Preferentially expressed antigen of melanoma (PRAME) in the development of diagnostic and therapeutic methods for hematological malignancies.Leuk Lymphoma. 2003 Mar;44(3):439-44. doi: 10.1080/1042819021000035725. Leuk Lymphoma. 2003. PMID: 12688312 Review.
-
PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.JAMA Ophthalmol. 2017 Jun 1;135(6):541-549. doi: 10.1001/jamaophthalmol.2017.0729. JAMA Ophthalmol. 2017. PMID: 28448663 Free PMC article.
Cited by
-
PRAME protein expression in DICER1-related tumours.J Pathol Clin Res. 2022 May;8(3):294-304. doi: 10.1002/cjp2.264. Epub 2022 Mar 16. J Pathol Clin Res. 2022. PMID: 35297207 Free PMC article.
-
Exploration of Reduced Mitochondrial Content-Associated Gene Signature and Immunocyte Infiltration in Colon Adenocarcinoma by an Integrated Bioinformatic Analysis.Front Genet. 2022 Apr 8;13:832331. doi: 10.3389/fgene.2022.832331. eCollection 2022. Front Genet. 2022. PMID: 35464857 Free PMC article.
-
Therapeutic targeting of PRAME with mTCRCAR T cells in acute myeloid leukemia.Blood Adv. 2023 Apr 11;7(7):1178-1189. doi: 10.1182/bloodadvances.2022008304. Blood Adv. 2023. PMID: 35984639 Free PMC article.
-
Vaccines for Non-Viral Cancer Prevention.Int J Mol Sci. 2021 Oct 9;22(20):10900. doi: 10.3390/ijms222010900. Int J Mol Sci. 2021. PMID: 34681560 Free PMC article. Review.
-
Targeting PRAME for acute myeloid leukemia therapy.Front Immunol. 2024 Mar 26;15:1378277. doi: 10.3389/fimmu.2024.1378277. eCollection 2024. Front Immunol. 2024. PMID: 38596687 Free PMC article. Review.
References
-
- Ikeda H, Lethé B, Lehmann F, et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity. 1997;6(2):199‐208. - PubMed
-
- Goodison S, Urquidi V. The cancer testis antigen PRAME as a biomarker for solid tumor cancer management. Biomark Med. 2012;6(5):629‐632. - PubMed
-
- Ortmann CA, Eisele L, Nückel H, et al. Aberrant hypomethylation of the cancer‐testis antigen PRAME correlates with PRAME expression in acute myeloid leukemia. Ann Hematol. 2008;87(10):809‐818. - PubMed
-
- Roman‐Gomez J, Jimenez‐Velasco A, Agirre X, et al. Epigenetic regulation of PRAME gene in chronic myeloid leukemia. Leuk Res. 2007;31(11):1521‐1528. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical